|
Founded: |
Ferring was first founded in Sweden in 1950 by Dr. Frederik Paulsen |
|
Headquarters: |
Switzerland |
|
International: |
Ferring International Center (Switzerland) International PharmaScience Center (Denmark) Production sites in eight countries (China, the Czech Republic, Denmark, Germany, Israel ,Mexico, Sweden and Switzerland). |
|
Market presence: |
In more than 40 countries |
|
Workforce: |
More than 2,500 employees worldwide |
|
2005 sales: |
EUR 688 Million |
|
Growth: |
Double-digit average annual growth rate over the last two decades |
Key therapeutic areas and products
|
Urology: |
MINIRIN (desmopressin) *, is the treatment of choice for bedwetting in children and nocturia in adults |
|
Infertility & Obstetrics:
|
MENOPUR (Menotropin)* (REPRONEX in the US) and BRAVELLE* (hFSH) are ovarian-stimulating treatments used in preparation for in-vitro fertilisation (IVF). TRACTOCILE (Atosiban)*, is used to treat pre-term (premature) labour |
|
Endocrinology:
|
ZOMACTON (Somatropin)*, is a recombinant human growth hormone used to treat growth failure in children. |
|
Gastroenterology:
|
PENTASA (mesalazine)*, is used for the treatment of inflammatory bowel diseases. GLYPRESSIN (terlipressin)*, for Bleeding Oesophageal Varices and (in some markets) for Hepatorenal syndrome. |
(* MINIRIN, MENOPUR, REPRONEX, BRAVELLE, TRACTOCILE, PENTASA, GLYPRESSIN and ZOMACTON are registered trademarks of Ferring BV and/or any of its affiliates.)
Research & Development
|
R&D investment: |
14-15 percent of net sales per annum |
|
R&D portfolio: |
|